Category: doing the right thing

Costly genotyping mistake forces lab to pull 3rd paper

KPSB_11_09_COVER.inddA few months ago, an author alerted us to two retractions — including one in PNAS — after realizing his team had been using plants affected by inadvertent genotyping errors for an entire year. He initially told us these were the only two papers affected, but more recently reached out to say he had to pull a follow-up article, as well.

Recently, Steven C. Huber contacted us about the newest retraction, noting he was submitting a notice to the editor of Plant Signaling and Behavior:

Continue reading Costly genotyping mistake forces lab to pull 3rd paper

Oh, well — “love hormone” doesn’t reduce psychiatric symptoms, say researchers in request to retract

psychiatry-research

It turns out, snorting the so-called “love hormone” may not help reduce psychiatric symptoms such as depression and anxiety.

At least, that’s the conclusion the authors of a 2015 meta-analysis, which initially found intranasal doses of oxytocin could reduce psychiatric symptoms, have now reached. After a pair of graduate students pointed out flaws in the paper, the authors realized they’d made some significant errors, and oxytocin shows no more benefit than placebo.

First author Stefan Hofmann from Boston University in Massachusetts explains further in a lengthy letter he sent to Psychiatry Research, which he passed on to us: Continue reading Oh, well — “love hormone” doesn’t reduce psychiatric symptoms, say researchers in request to retract

Author asks to retract nearly 20-year old paper over figure questions, lack of data

journal-of-biological-chemistryThe last author of a 1999 paper has asked the journal to retract it less than one month after a user raised questions about images on PubPeer.

Yesterday, last author Jim Woodgett posted a note on the site saying the author who generated the figures in question could not find the original data, and since he agreed the images appeared “suspicious,” he had contacted the journal to retract the paper.

Here’s the note from Woodgett, based at Lunenfeld-Tanenbaum
Research Institute at Mount Sinai Hospital in Toronto: Continue reading Author asks to retract nearly 20-year old paper over figure questions, lack of data

Doing the right thing: Authors pull psych review after finding inaccuracies

Two psychology researchers are retracting a meta-analysis after discovering errors they believe may affect the conclusions.

We’re giving this a “doing the right thing” nod, as last author Pankaj Patel of Villanova University in Pennsylvania contacted us about his plan to retract the paper, and resubmit for publication once he and co-author Sherry Thatcher — at the University of South Carolina — have performed all their recalculations.

Here’s the retraction notice for “Demographic faultlines: A meta-analysis of the literature,” published in the Journal of Applied Psychology: Continue reading Doing the right thing: Authors pull psych review after finding inaccuracies

Authors retract study with contaminated cell lines

MBoCAuthors of a molecular biology paper have pulled it after realizing that their cell lines were contaminated.

According to the notice in Molecular Biology of the Cell (MBoC), the contamination occurred by “unknown means” in the senior authors’ laboratory, who told us the mistake was a difficult one to catch. He added that they discovered the problem after other researchers published conflicting results.

He also noted that the contaminated cell lines were not used for experiments in any other papers.

Here’s the retraction notice, issued on August 1: Continue reading Authors retract study with contaminated cell lines

Second retraction for bone researcher with lifetime funding ban

via WCH
via WCH

A researcher banned from funding by a Canadian agency for misconduct has earned her second retraction, after a reanalysis uncovered problems with the paper’s conclusions.

The retraction follows an investigation by Sophie Jamal‘s former workplace, the Women’s College Hospital in Toronto, which has led to a recent retraction of a JAMA paper due to data manipulation, and a lifetime funding ban from the Canadian Institutes of Health Research (CIHR).

The latest retraction stemmed from a re-analysis of the paper by the Canadian Multicentre Osteoporosis Study Group, of which the paper was a part; all authors but Jamal have requested the retraction. In the notice, the authors say that they believe no patients were harmed as a result of the “possibly invalid conclusions” in the paper, which showed patients with kidney problems were at higher risk of bone loss. A researcher told us a third paper by Jamal is also due to be retracted soon.

Here’s the retraction notice, issued by the American Journal of Kidney Diseases (AJKD): Continue reading Second retraction for bone researcher with lifetime funding ban

Nutrition study pulled after statistical flaws emerge

Nutrition JournalA paper that suggested that eating flaxseed could reduce inflammation in men at risk of heart disease has been retracted, after researchers pointed out the paper’s flaws.

The retraction is part of a large initiative on the part of nutrition researcher David Allison and colleagues to clean up the literature, which we’ve previously covered. Regarding this paper, he told us:

When we looked at the study…it was very clear that the statistical methods used were not correct. These are not matters of debate or opinion, these are just…verifiably incorrect.

The Nutrition Journal published the paper in January 2015, and retracted it in June 2016, one day after publishing a letter by Allison and a colleague critiquing the paper. 

Here’s the retraction notice for “Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study:” Continue reading Nutrition study pulled after statistical flaws emerge

“Great shock and sadness:” Publishing gadfly to retract paper for duplication

untitledA vociferous advocate for correcting the literature — who has been banned by two publishers for his persistent communications — has asked journals to retract one paper and correct three others for duplications.

After a reader flagged his 2004 paper on PubPeer last month, author Jaime Teixeira da Silva “immediately” contacted the journal to alert it that the paper had been duplicated, as he noted on a recent comment on our site:

Continue reading “Great shock and sadness:” Publishing gadfly to retract paper for duplication

Genotyping mistake costs lab two papers and year of work

PNASResearchers are retracting two papers about molecular signalling in plants — including one from the Proceedings of the National Academy of Sciences (PNAS) — after discovering some inadvertent genotyping errors. But that was only after they used the problematic plants for an entire year without realizing they’d made a mistake.

In a pair of refreshingly transparent and detailed notices, the authors explain that the transgenic plants used in the papers included genotyping errors, which invalidated their findings. According to the notices, first author Man-Ho Oh generated the problematic transgenic plants, while corresponding author Steven C. Huber, based at University of Illinois, Urbana-Champaign (UIUC), took responsibility for omitting some critical oversight.

Huber told us that there were only two papers that used the transgenic plants in question, so no other retractions will be forthcoming.

Here’s the notice in PNAS for “Autophosphorylation of Tyr-610 in the receptor kinase BAK1 plays a role in brassinosteroid signaling and basal defense gene expression:”  Continue reading Genotyping mistake costs lab two papers and year of work

Authors retract non-reproducible Cell paper

CellAuthors have retracted a paper from Cell after they were unable to reproduce data in two figures, compromising their confidence in some of the findings.

The authors revisited their experiments after another lab was unable to replicate their data, about proteins that may play a role in lung cancer.

The first author told Nature News in 2013 that the paper may have helped her secure her current position at the Novartis Institutes for Biomedical Research in Massachusetts.

Pulling “Cytohesins are cytoplasmic ErbB receptor activators” appears to be a case of doing the right thing, given the detailed retraction notice:

Continue reading Authors retract non-reproducible Cell paper